Skip to main content
Premium Trial:

Request an Annual Quote

Don't Wait Your Turn

One of DrugMonkey's readers relayed a bit of a situation. The reader is working on an R01 but a colleague who sits on a study section told the reader to "definitely wait two years so [the reader] can get things rolling before applying." DrugMonkey says that is nonsensical advice and that R01 funding is needed to get and keep a lab working and that waiting around isn't going to accomplish much. That little bit of extra preliminary data is not really going to affect your chance of receiving funding -- going through multiple grant cycles is common and other factors, such as reviewers' interest, also affect awards. DrugMonkey suspects this may be a case of bias against new PIs. "Strategically, I would say that if you just give up and accept this, there is zero chance of getting your award. If you submit anyway, at least you have a nonzero chance of someone like me being on the panel and arguing against this unjustified bias/tradition," he writes.

The Scan

CDC Calls Delta "Variant of Concern"

CNN reports the US Centers for Disease Control and Prevention now considers the Delta variant of SARS-CoV-2 to be a "variant of concern."

From FDA to Venture Capital

Former FDA Commissioner Stephen Hahn is taking a position at a venture capital firm, leading some ethicists to raise eyebrows, according to the Washington Post.

Consent Questions

Nature News writes that there are questions whether informed consent was obtained for some submissions to a database of Y-chromosome profiles.

Cell Studies on Multimodal Single-Cell Analysis, Coronaviruses in Bats, Urban Microbiomes

In Cell this week: approach to analyze multimodal single-cell genomic data, analysis of bat coronaviruses, and more.